Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOK | Q9UQ07 | 8/20 | 0.60 |
| ▸ | MTOR | P42345 | 7/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.56 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2370486 | 0.86 | MTOR (0.70) | MTORPIK3CAPIK3CG | |
| SCHEMBL3991686 | 0.84 | TDP1 (0.51) | MTORPIK3CAPIK3CGMAPTKDM4E | |
| SCHEMBL4127408 | 0.83 | PIK3CA (0.59) | MOKMTORPIK3CAPIK3CGJAK2 | |
| SCHEMBL8084906 | 0.82 | MOK (0.60) | MOKMTORPIK3CAPIK3CGJAK2 | |
| SCHEMBL1311610 | 0.81 | PIK3CA (0.77) | MTORPIK3CAPIK3CGMAPTGAA | |
| SCHEMBL3991612 | 0.80 | MTOR (0.46) | MTORPIK3CAPIK3CGJAK2KDM4E | |
| SCHEMBL13588580 | 0.78 | MOK (0.61) | MOKMTORPIK3CAJAK2MAPT | |
| SCHEMBL3450472 | 0.78 | KDM4E (0.54) | MTORPIK3CAPIK3CGMAPTKDM4E | |
| SCHEMBL3452085 | 0.78 | NPSR1 (0.65) | MTORPIK3CAMAPTKDM4EALDH1A1 | |
| SCHEMBL3998571 | 0.77 | ALDH3A1 (0.53) | MTORPIK3CAPIK3CGKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | MOK 1399/4885MTOR 919/4885PIK3CA 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.